Infanrix Polio (Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads)

The vaccine contains diphtheria and tetanus toxoids, acellular pertussis antigens (filamentous haemagglutinin and pertussis toxoid) adsorbed on aluminium hydroxide, and inactivated poliovirus types 1‑3. These components stimulate the immune system to produce specific antibodies that neutralise the bacterial toxins and poliovirus, establishing long‑lasting protection.

The dose and schedule of Infanrix Polio are determined by the prescribing clinician based on the approved immunisation timetable for the region. Typically, the vaccine is given as a series of intramuscular injections at specific ages, but exact timing and volume are set by the healthcare professional.

Safety data for Infanrix Polio in pregnant or breastfeeding women are limited. The vaccine is generally not recommended for routine use during pregnancy unless the potential benefit to the mother outweighs any theoretical risk to the fetus. Breastfeeding is not a contraindication, but clinicians should assess each case individually.

To order Infanrix Polio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, cold‑chain shipping details and any necessary import documentation.

Infanrix Polio combines DTPa (diphtheria, tetanus, acellular pertussis) with IPV (inactivated poliovirus) in a single injection, reducing the number of shots compared with administering separate DTPa and IPV vaccines. Alternative products such as Pentacel also provide DTPa‑IPV but may differ in antigen concentrations or adjuvant composition, which can affect immunogenicity and reactogenicity profiles.

Infanrix Polio must be stored at 2‑8 °C (refrigerated) and protected from light. The vaccine should never be frozen or shaken. Vials should be kept in their original packaging until use, and any unused portion should be discarded according to local regulations after the recommended in‑use time.

The vaccine is given by intramuscular injection, usually into the anterolateral thigh for infants and young children. The administration technique follows standard aseptic procedures, and the injection site should be observed for local reactions after the dose is given.

The most serious adverse events reported with Infanrix Polio include severe allergic reactions such as anaphylaxis, high‑grade fever, seizures, and rare neurologic complications like encephalopathy or hypotonic‑hyporesponsive episodes. Any signs of a serious reaction require immediate medical evaluation.

Infanrix Polio should not be given to individuals with a known severe allergy to any vaccine component, including the aluminium adjuvant. It is also contraindicated in persons who have experienced a previous severe reaction to a DTPa‑IPV vaccine. Clinicians should assess each patient’s medical history before vaccination.